EWING, N.J., May 16, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) announced that data from its Phase 3 study of the pharmacokinetics and safety of subcutaneous testosterone enanthate ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...
Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research indicates for men evaluating prescription testosterone pathways heading into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback